 |
인쇄하기
취소
|
Novartis Korea to launch IBS medication in domestic market
Novartis Korea, a Korean unit of Switzerland-based multinational pharmaceutical firm, said it would soon roll out Zelmac (tegasorod) into domestic pharmaceutical market.
Tegasorod, serotonin type-4 (5-hydroxytryptamine) agonist, is an oral medication for the treatment of constipation-predominant irritable bowel syndrome (IBS) in women. The drug was approved by the US FDA in July 2002.
I...
Tegasorod, serotonin type-4 (5-hydroxytryptamine) agonist, is an oral medication for the treatment of constipation-predominant irritable bowel syndrome (IBS) in women. The drug was approved by the US FDA in July 2002.
I...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.